The Pan American Health Organization (PAHO) has issued a critical epidemiological alert warning of heightened dengue outbreak risks across the Americas. This alert points to the growing prevalence of the DENV-3 serotype in numerous countries, encouraging immediate action to bolster surveillance, diagnosis, and clinical management.
The Spread of DENV-3 in the Americas
The DENV-3 serotype has emerged in several American countries, including Brazil, Colombia, Costa Rica, Guatemala, Mexico, and Peru. Argentina reported its first cases in 2024, marking the introduction of this serotype into the country. Brazil and Colombia, in particular, have experienced a surge in DENV-3 cases, notably among children. Other Central American and Caribbean nations have also detected the serotype, which is linked to severe dengue forms, even in initial infections. These developments signal a significant public health concern.
Current Situation and Preventive Measures
In 2024, the Americas faced over 13 million dengue cases, with 22,684 classified as severe (0.17% of the total) and 8,186 resulting in fatalities (case fatality rate of 0.063%). Early 2025 data showed 238,659 reported cases across 23 countries and territories, primarily concentrated in Brazil (87%), followed by Colombia (5.6%), Nicaragua (2.5%), Peru (2.5%), and Mexico (2.5%). Among these, 263 were severe, and 23 resulted in deaths. PAHO emphasizes the need for intensified vector control, improved diagnostic tools, and early medical interventions to mitigate the impact of potential outbreaks.
Public education is also crucial. Campaigns aimed at reducing exposure to mosquito vectors and eliminating breeding sites form part of the recommended strategies. These measures are vital in preventing transmission and controlling dengue spread.
Vaccination and Continuous Monitoring
The situation with dengue vaccination is complex. The TAK-003 dengue vaccine, in use in some regions, offers lower protection against DENV-3, especially in children who have not been previously infected. This underscores the importance of careful vaccination practices and continuous monitoring for any adverse effects. PAHO continues to closely monitor the circulation of DENV-3 and other serotypes, providing ongoing support to countries in their efforts to control and respond effectively to dengue outbreaks.
Healthcare systems must be prepared to manage the expected increase in dengue cases and mitigate the risk of severe complications. The proactive approach taken by PAHO is essential in safeguarding public health across the Americas.
For more information, visit PAHO’s official website.
Stay informed about the latest health news and global epidemics by subscribing to our newsletter. Share your thoughts and experiences in the comments below. Help us spread awareness by sharing this article on social media. Your engagement helps us reach more people.